RATIONALE: Nuclear receptors play a critical role in the regulation of inflammation, thus representing attractive targets for the treatment of asthma. OBJECTIVE: In this study, we assess the potential regulatory function of retinoid-related orphan receptor alpha (RORalpha) in the adaptive immune response using ovalbumin (OVA)-induced airway inflammation as a model. METHODS: Allergen-induced inflammation was compared between wild-type (WT) and staggerer (RORalpha(sg/sg)) mice, a natural mutant strain that is deficient in RORalpha expression. MEASUREMENTS AND MAIN RESULTS: Despite robust increases in OVA-specific IgE, RORalpha(sg/sg) mice developed significantly less pulmonary inflammation, mucous cell hyperplasia, and eosinophilia compared with similarly treated WT animals. Induction of Th2 cytokines, including interleukin (IL)-4, IL-5, and IL-13, was also significantly less in RORalpha(sg/sg) mice. Microarray analysis using lung RNA showed increased expression of many genes, previously implicated in inflammation, in OVA-treated WT mice. These include mucin Muc5b, the chloride channel calcium-activated 3 (Clca3), macrophage inflammatory protein (MIP) 1alpha and 1beta, eotaxin-2, serum amyloid A3 (Saa3), and insulin-like growth factor 1 (Igf1). These genes were induced to a greater extent in OVA-treated WT mice relative to RORalpha(sg/sg) mice. CONCLUSIONS: Our study demonstrates that mice deficient in RORalpha exhibit an attenuated allergic inflammatory response, indicating that RORalpha plays a critical role in the development of Th2-driven allergic lung inflammation in mice, and suggests that this nuclear receptor should be further evaluated as a potential asthma target.
RATIONALE: Nuclear receptors play a critical role in the regulation of inflammation, thus representing attractive targets for the treatment of asthma. OBJECTIVE: In this study, we assess the potential regulatory function of retinoid-related orphan receptor alpha (RORalpha) in the adaptive immune response using ovalbumin (OVA)-induced airway inflammation as a model. METHODS: Allergen-induced inflammation was compared between wild-type (WT) and staggerer (RORalpha(sg/sg)) mice, a natural mutant strain that is deficient in RORalpha expression. MEASUREMENTS AND MAIN RESULTS: Despite robust increases in OVA-specific IgE, RORalpha(sg/sg) mice developed significantly less pulmonary inflammation, mucous cell hyperplasia, and eosinophilia compared with similarly treated WT animals. Induction of Th2 cytokines, including interleukin (IL)-4, IL-5, and IL-13, was also significantly less in RORalpha(sg/sg) mice. Microarray analysis using lung RNA showed increased expression of many genes, previously implicated in inflammation, in OVA-treated WT mice. These include mucin Muc5b, the chloride channel calcium-activated 3 (Clca3), macrophage inflammatory protein (MIP) 1alpha and 1beta, eotaxin-2, serum amyloid A3 (Saa3), and insulin-like growth factor 1 (Igf1). These genes were induced to a greater extent in OVA-treated WT mice relative to RORalpha(sg/sg) mice. CONCLUSIONS: Our study demonstrates that mice deficient in RORalpha exhibit an attenuated allergic inflammatory response, indicating that RORalpha plays a critical role in the development of Th2-driven allergic lung inflammation in mice, and suggests that this nuclear receptor should be further evaluated as a potential asthma target.
Authors: Richard Leigh; Russ Ellis; Jennifer N Wattie; Jeremy A Hirota; Klaus I Matthaei; Paul S Foster; Paul M O'Byrne; Mark D Inman Journal: Am J Respir Crit Care Med Date: 2003-12-30 Impact factor: 21.405
Authors: Audrey H Poon; Catherine Laprise; Mathieu Lemire; Alexandre Montpetit; Donna Sinnett; Erwin Schurr; Thomas J Hudson Journal: Am J Respir Crit Care Med Date: 2004-07-28 Impact factor: 21.405
Authors: Cleber D L Ramos; Claudio Canetti; Janeusa T Souto; João S Silva; Cory M Hogaboam; Sergio H Ferreira; Fernando Q Cunha Journal: J Leukoc Biol Date: 2005-04-14 Impact factor: 4.962
Authors: Anneke ten Brinke; Aeilko H Zwinderman; Peter J Sterk; Klaus F Rabe; Elisabeth H Bel Journal: Am J Respir Crit Care Med Date: 2004-06-23 Impact factor: 21.405
Authors: Ying Shi; Jiaofei Cao; Jane Gao; Liang Zheng; Andrew Goodwin; Chang Hyoek An; Avignat Patel; Janet S Lee; Steven R Duncan; Naftali Kaminski; Kusum V Pandit; Ivan O Rosas; Augustine M K Choi; Danielle Morse Journal: Am J Respir Crit Care Med Date: 2012-06-28 Impact factor: 21.405
Authors: Se Kyu Oh; Dongha Kim; Kyeongkyu Kim; Kyungjin Boo; Young Suk Yu; Ik Soo Kim; Yoon Jeon; Sun-Kyoung Im; Su-Hyung Lee; Ji Min Lee; Younhee Ko; Ho Lee; Daechan Park; Sungsoon Fang; Sung Hee Baek Journal: Proc Natl Acad Sci U S A Date: 2019-09-30 Impact factor: 11.205
Authors: S Bruhn; F Barrenäs; R Mobini; B A Andersson; S Chavali; B S Egan; E Hovig; G K Sandve; M A Langston; G Rogers; H Wang; M Benson Journal: Allergy Date: 2011-09-15 Impact factor: 13.146
Authors: Maria B Sukkar; Md Ashik Ullah; Wan Jun Gan; Peter A B Wark; Kian Fan Chung; J Margaret Hughes; Carol L Armour; Simon Phipps Journal: Br J Pharmacol Date: 2012-11 Impact factor: 8.739